THOUSAND OAKS, Calif., Dec. 14, 2018 /PRNewswire/ — Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Nplate (romiplostim) for the treatment of pediatric…Original Article
FDA Approves Nplate (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia
